Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | MGLL | Q99685 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | UBE2M | P61081 | 1/20 | 0.54 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10723816 | 0.84 | RAB9A (0.80) | RAB9AMGLLTDP1CYP2C9CYP2C19 | |
| SCHEMBL5658973 | 0.84 | RAB9A (0.72) | RAB9AMGLLTDP1MAPTALDH1A1 | |
| SCHEMBL10274559 | 0.84 | RAB9A (0.72) | RAB9AMGLLTDP1CYP2C9CYP2C19 | |
| SCHEMBL23775392 | 0.84 | RAB9A (0.72) | RAB9AMGLLTDP1CYP2C9CYP2C19 | |
| SCHEMBL26387389 | 0.84 | RAB9A (0.72) | RAB9AMGLLTDP1CYP2C9CYP2C19 | |
| SCHEMBL5766611 | 0.83 | RAB9A (0.70) | RAB9AMGLLTDP1CYP2C9CYP2C19 | |
| SCHEMBL11893518 | 0.83 | ALDH1A1 (0.76) | RAB9AMGLLCYP2C9CYP2C19HTR2B | |
| SCHEMBL7311576 | 0.82 | RAB9A (0.69) | RAB9AMGLLGAAMAPTKDM4E | |
| SCHEMBL8375940 | 0.81 | RAB9A (0.68) | RAB9AMGLLTDP1CYP2C9CYP2C19 | |
| SCHEMBL4171372 | 0.81 | KMT2A (0.73) | RAB9AMGLLTDP1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| CN-102498099-A | HSL inhibitors useful in the treatment of diabetes | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| EP-2805955-A1 | 1-OXO/ACYLATION-14-ACYLATED ORIDONIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Hangzhou Bensheng Pharmaceutical Co., Ltd. (CN) | 2014-11-26 | — | — | EP | disclosed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| CN-102498099-A | HSL inhibitors useful in the treatment of diabetes | HOFFMANN LA ROCHE | 2012-06-13 | — | — | CN | disclosed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | RAB9A 3818/4885MGLL 6/4885TDP1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.